Immunotherapy and immunoevasion of colorectal cancer

被引：30
作者：
Al Zein, Mohammad [1 ]
Boukhdoud, Mona [1 ]
Shammaa, Hadi [1 ]
Mouslem, Hadi [1 ]
El Ayoubi, Lemir Majed [1 ]
Iratni, Rabah [2 ]
Issa, Khodr [3 ]
Khachab, Maha [4 ]
Assi, Hazem I. [5 ]
Sahebkar, Amirhossein [6 ,7 ]
Eid, Ali H. [8 ]
机构：
[1] Lebanese Univ, Fac Med Sci, Beirut, Lebanon
[2] United Arab Emirates Univ, Coll Sci, Dept Biol, Al Ain, U Arab Emirates
[3] Univ Lille, Prote Inflammatory Response Mass Spectrometry, INSERM U 1192, Lille, France
[4] Univ Balamand, Fac Med, Balamand, Lebanon
[5] Amer Univ, Fac Med, Beirut Med Ctr, Beirut, Lebanon
[6] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran
[7] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran
[8] Qatar Univ, Coll Med, Dept Basic Med Sci, QU Hlth, Doha, Qatar
来源：
DRUG DISCOVERY TODAY | 2023年 / 28卷 / 09期
关键词：
colorectal cancer; CTLA-4; immune checkpoint inhibitor; cancer vaccines; PD-1; adoptive cell therapy; TUMOR-ASSOCIATED MACROPHAGES; IMMUNE-CHECKPOINT INHIBITORS; IMMUNOGENIC CELL-DEATH; CLASS-I EXPRESSION; T-CELL; MICROSATELLITE INSTABILITY; BRAF MUTATION; MOLECULAR SUBTYPES; CLINICAL IMPACT; OPEN-LABEL;
D O I：
10.1016/j.drudis.2023.103669
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The tremendous success of immunotherapy in clinical trials has led to its establishment as a new pillar of cancer therapy. However, little clinical efficacy has been achieved in microsatellite stable colorectal cancer (MSS-CRC), which constitutes most CRC tumors. Here, we discuss the molecular and genetic heterogeneity of CRC. We review the immune escape mechanisms, and focus on the latest advances in immunotherapy as a treatment modality for CRC. By providing a better understanding of the tumor microenvironment (TME) and the molecular mechanisms underlying immunoevasion, this review offers an insight into developing therapeutic strategies that are effective for patients with various subsets of CRC.
引用
收藏
页数：16
相关论文
共 146 条
  • [41] Grosso Joseph F, 2013, Cancer Immun, V13, P5
  • [42] The consensus molecular subtypes of colorectal cancer
    Guinney, Justin
    Dienstmann, Rodrigo
    Wang, Xin
    de Reynies, Aurelien
    Schlicker, Andreas
    Soneson, Charlotte
    Marisa, Laetitia
    Roepman, Paul
    Nyamundanda, Gift
    Angelino, Paolo
    Bot, Brian M.
    Morris, Jeffrey S.
    Simon, Iris M.
    Gerster, Sarah
    Fessler, Evelyn
    Melo, Felipe De Sousa E.
    Missiaglia, Edoardo
    Ramay, Hena
    Barras, David
    Homicsko, Krisztian
    Maru, Dipen
    Manyam, Ganiraju C.
    Broom, Bradley
    Boige, Valerie
    Perez-Villamil, Beatriz
    Laderas, Ted
    Salazar, Ramon
    Gray, Joe W.
    Hanahan, Douglas
    Tabernero, Josep
    Bernards, Rene
    Friend, Stephen H.
    Laurent-Puig, Pierre
    Medema, Jan Paul
    Sadanandam, Anguraj
    Wessels, Lodewyk
    Delorenzi, Mauro
    Kopetz, Scott
    Vermeulen, Louis
    Tejpar, Sabine
    [J]. NATURE MEDICINE, 2015, 21 (11) : 1350 - 1356
  • [43] Role of dendritic cells in progression and clinical outcome of colon cancer
    Gulubova, Maya V.
    Ananiev, Julian R.
    Vlaykova, Tatyana I.
    Yovchev, Yovcho
    Tsoneva, Vanya
    Manolova, Irena M.
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (02) : 159 - 169
  • [44] The Role of Tumor-Infiltrating B Cells in Tumor Immunity
    Guo, Fei Fei
    Cui, Jiu Wei
    [J]. JOURNAL OF ONCOLOGY, 2019, 2019
  • [45] Oncolytic herpes simplex virus type-1 expressing IL-12 efficiently replicates and kills human colorectal cancer cells
    Haghighi-Najafabadi, Nasrin
    Roohvand, Farzin
    Nosrati, Mohammad Sadegh Shams
    Teimoori-Toolabi, Ladan
    Azadmanesh, Kayhan
    [J]. MICROBIAL PATHOGENESIS, 2021, 160
  • [46] Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines
    Halama, Niels
    Braun, Monika
    Kahlert, Christoph
    Spille, Anna
    Quack, Christian
    Rahbari, Nuh
    Koch, Moritz
    Weitz, Juergen
    Kloor, Matthias
    Zoernig, Inka
    Schirmacher, Peter
    Brand, Karsten
    Grabe, Niels
    Falk, Christine S.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (04) : 678 - 689
  • [47] Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy
    Hao, Meixi
    Hou, Siyuan
    Li, Weishuo
    Li, Kaiming
    Xue, Lingjing
    Hu, Qifan
    Zhu, Lulu
    Chen, Yue
    Sun, Hongbin
    Ju, Caoyun
    Zhang, Can
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (571)
  • [48] Deregulation of HLA-I in cancer and its central importance for immunotherapy
    Hazini, Ahmet
    Fisher, Kerry
    Seymour, Len
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [49] Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors
    Hombach, Andreas A.
    Rappl, Gunter
    Abken, Hinrich
    [J]. MOLECULAR THERAPY, 2019, 27 (10) : 1825 - 1835
  • [50] Improved Endpoints for Cancer Immunotherapy Trials
    Hoos, Axel
    Eggermont, Alexander M. M.
    Janetzki, Sylvia
    Hodi, F. Stephen
    Ibrahim, Ramy
    Anderson, Aparna
    Humphrey, Rachel
    Blumenstein, Brent
    Old, Lloyd
    Wolchok, Jedd
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (18): : 1388 - 1397
12345678910